Coverage
Filings
| Filing | Date |
|---|---|
| EMA grants PRIME Designation for GSK’227 | 16 Dec 2024 |
| Jemperli receives US FDA breakthrough designation | 16 Dec 2024 |
| Director/PDMR Shareholding | 12 Dec 2024 |
| Nucala COPD submission accepted by US FDA | 9 Dec 2024 |
| Blenrep combination China filing acceptance | 9 Dec 2024 |
| Overall survival data presented for Blenrep | 9 Dec 2024 |
| Zhifei China collaboration revised and extended | 5 Dec 2024 |
| Total Voting Rights |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 2 Dec 2024 |
| Director/PDMR Shareholding | 2 Dec 2024 |
| GSK liquid meningitis vaccine authorised in EU | 27 Nov 2024 |
| Blenrep combinations accepted for US FDA review | 25 Nov 2024 |
| Japan approves first RSV vaccine for adults 50-59 | 22 Nov 2024 |